Lymphoid origin of intrinsically activated plasmacytoid dendritic cells in mice.


1 Department of Chemical Engineering, The University of Texas at Austin, Austin TX, USA.
2 Department of Biomedical Engineering, and Livestrong Cancer Institutes, The University of Texas at Austin, Austin TX, USA.
3 Department of Molecular Biosciences, The University of Texas at Austin, Austin TX, USA.

Running Title: pDC lymphoid development

Corresponding Authors:

Haley O. Tucker, Department of Molecular Biosciences. The University of Texas at Austin, 1 University Station A5000, Austin TX 78712, USA. Phone: (512) 475-7706; Fax (512) 475-7707; E-mail: haleytucker@austin.utexas.edu

Joseph D. Dekker, Department of Molecular Biosciences. The University of Texas at Austin, 1 University Station A5000, Austin TX 78712, USA. Phone: (505)4637855; ORCID: orcid.org/0000-0002-2068-3529; E-mail: joedekker@gmail.com

S. Stephen Yi, Livestrong Cancer Institutes, and Department of Biomedical Engineering, The University of Texas at Austin, Austin TX 78712, USA. Phone: (512) 495-5245; E-mail: stephen.yi@austin.utexas.edu
Abstract

We identified a novel mouse plasmacytoid dendritic cell (pDC) lineage derived from the common lymphoid progenitors (CLPs) that is dependent on expression of \textit{BCL11A}. These CLP-derived pDCs, which we refer to as \textquotedblleft B-pDCs\textquotedblright, have a unique gene expression profile that includes hallmark B cell genes, normally not expressed in conventional pDCs. Despite expressing most classical pDC markers such as SIGLEC-H and PDCA1, B-pDCs lack IFN-\(\alpha\) secretion, exhibiting a distinct inflammatory profile. Functionally, induce T cell proliferation more robustly than canonical pDCs following Toll-like receptor 9 (TLR9) engagement. B-pDCs also display elevated levels of the cell-surface receptor tyrosine kinase AXL, mirroring human AXL\(^+\) transitional DCs in function and transcriptional profile. Murine B-pDCs therefore represent a phenotypically and functionally distinct CLP-derived DC lineage specialized in T cell activation and previously not described in mice.

Introduction

Plasmacytoid dendritic cells (pDCs) specialize in the production of type I interferons (IFNs) and promote antiviral immune responses following engagement of pattern recognition receptors. They have been mainly implicated in the pathogenesis of autoimmune diseases that are characterized by a type I IFN signature (notably, IFN-\(\alpha\)). Yet, pDCs have also been shown to be able to induce tolerogenic immune responses\(^5\text{-}^8\). Due to the clinical significance of pDCs, several studies aimed at mapping pDC lineage derivation have emerged recently. Yet, a complete understanding of pDC development and their existing subsets in mice is still lacking. The transcription factor 4 (TCF4) is required for pDC development and for lineage identity\(^9\text{-}^{11}\). TCF4 is a component of a multiprotein complex that includes both positive and negative regulators\(^6\text{-}^{12}\). One of these components, the transcription factor BCL11a, which is also
essential for B cell development, induces TCF4 transcription and initiates a positive feedback loop with TCF4 to maintain pDC lineage commitment and function.

Unlike their conventional dendritic cell (cDC) counterparts, canonical pDCs express transcriptional regulators and markers associated with B-lymphocyte development in addition to BCL11a (e.g. B220, SPIB). These features, along with established generation of pDCs from myeloid restricted precursors, have made it difficult to define pDC lineage affiliation. This has led to the hypothesis that pDC subsets may have distinct origins derived from either the Common Lymphoid Progenitor (CLP) or the Common Myeloid Progenitor (CMP). Beyond the complex nature of their lineage, pDCs with different functional attributes (e.g. variable IFN-α expression levels) or different surface markers (e.g. CD19+ pDCs detected in tumor-draining lymph nodes) have also been identified.

On par with the ever-increasing heterogeneity described within pDC populations, a novel AXL+ dendritic cell (DC) population with many pDC-like properties has recently been discovered in human blood. While AXL+ DCs express many canonical pDC markers (e.g. CD123, BDCA2/CD303), they also express CD2, the Ig-like lectins SIGLEC1 and SIGLEC6, as well as the activation marker CD81. In a separate study, AXL+ DCs were shown to express high levels of CD5 and CD81, two glycoproteins normally associated with the B cell receptor (BCR) signaling complex. The origin of AXL+ transitional DCs is currently unclear and the presence of a homologous population in mice remains muddled. Here, we report the identification of a lymphoid-derived pDC subset (B-pDCs) that shares inflammatory features with myeloid derived Axl+ pDC populations in mice. We also demonstrate an in vivo requirement for Bcl11a in the transcriptional specification of B-pDCs.
Results

We previously demonstrated that conditional deletion of Bcl11a in the hematopoietic stem cell (HSC) compartment mediated by Vav-1-Cre or by inducible Mx1-Cre recombinase results in complete abolishment of pDC development\textsuperscript{14}. Spurred by previous speculation of pDC origin from the CLP\textsuperscript{17,20}, we next selectively deleted floxed (\textsuperscript{F}) Bcl11a alleles in the late CLP stage\textsuperscript{24,25} as mediated by mb1-Cre \textit{in vivo}. Expression of the \textit{mb}1 gene (CD79a) initiates at the LY6D\textsuperscript{+} CLP stage, in B-cell-biased lymphoid progenitors (BLPs)\textsuperscript{26}, downstream of LY6D\textsuperscript{–} CLPs (Fig. S1). Bcl11a\textsuperscript{F/F}mb1-Cre mice (cKO) and littermate controls were examined for pDC frequencies among nucleated cells in the bone marrow (BM). B220\textsuperscript{+}PDCA1\textsuperscript{+} pDCs (all found to be CD11c\textsuperscript{int}) were consistently and significantly reduced by an average of \textasciitilde25\% (24.8 ± 2.4\%) in cKO mice relative to littermates (Fig. 1A-B). A near complete loss of B cells (B220\textsuperscript{hi} PDCA1\textsuperscript{–}) served as a gauge of \textit{mb}1-Cre deletion efficiency (Fig. 1A-B). Taken together, these data indicate that a significant proportion of pDCs are derived from BLP progenitors and are \textit{Bcl}11\textit{a} dependent.

To expand these \textit{in vivo} observations, and to confirm that this defect is intrinsic to hematological progenitor cells, we transferred BM from either BCL11A-sufficient reporter control mice (\textit{mb}1-Cre-YFP) or BCL11A-deficient cKO mice (Bcl11a\textsuperscript{F/F}mb1-Cre-YFP) into lethally irradiated wild type C57BL/6J recipients. After 8 weeks, <10\% of B cells (B220\textsuperscript{+}PDCA1\textsuperscript{+}) in the spleens of \textit{mb}1-Cre-YFP recipients were YFP\textsuperscript{–}, confirming elimination of recipient hematopoiesis (Fig. 1D-E). As expected, Bcl11a\textsuperscript{F/F}mb1-Cre-YFP BM resulted in significantly reduced B cell and pDC cellularity compared to \textit{mb}1-Cre-YFP controls, whereas BCL11A-sufficient (YFP\textsuperscript{–}) pDCs persisted (Fig. 1C, 1E-F). Approximately 1/3 of pDCs in the spleen of wild-type chimeras were YFP\textsuperscript{+} compared to only 1/5 in BM (Fig. 1G).
increased fraction of YFP⁺ pDCs in the spleen suggests that CLP-derived pDCs preferentially home to that organ. Other hematopoietic lineages were capable of development in normal numbers and contained a paucity of YFP⁺ cells (Fig. S2). Of note, BCL11A-deficient progenitors yielded higher splenic T cell chimerism at the expense of B cells and pDCs, but less than 2% of T cells were YFP⁺ (S2, and not shown). This indicated that mb1-cre expression occurs subsequent to T-B lineage divergence, consonant with previous observations²⁶, ⁶⁸, ⁶⁹ and our mb1-cre progenitor analysis in which YFP⁺ cells are confined to CLP stage (Fig. S1). Because of their exclusive lymphoid derivation post T-B bifurcation, we were prompted hereafter to refer to this pDC lineage as “B-pDC.”

Relative to conventional pDCs, resting B-pDCs express higher levels of activation markers and MHC Class II (Fig 2A-B) suggesting that they may be primed for immediate response to pro-inflammatory signals. To test this hypothesis, we delivered TLR9 ligand (CpG:ODN) into mb1-Cre-YFP mice via tail vein injection, and splenic pDCs were phenotyped via flow cytometry 24 hours later. While both pDC and B-pDC compartments expanded relative to controls (Fig. 2C-D), the YFP⁺ B-pDC fraction increased almost 2-fold above that of the YFP⁻ pDC fraction in numbers (Fig. 2E). Additionally, B-pDCs had markedly enhanced expression of CD83, and CD86 levels upon activation, (Fig. 2F-G). These results suggested that relative to bulk YFP negative pDCs, B-pDCs are intrinsically activated and primed for rapid expansion upon TLR9 engagement. To confirm the functional phenotype of B-pDCs, we tested their ability to secrete cytokines known to be elicited by pDCs after Toll-like receptor (TLR) engagement. Specifically, we tested each pDC lineage for the production of IFN-α or IL-12p40 when activated by TLR9-bound CpG oligonucleotides. We sorted B-pDCs and pDCs, engaged TLR9 with CpG:ODNs for 24 hours and collected supernatant for
cytokine specific ELISAs. IFN-α production was almost negligible in B-pDC (p<0.0001, Fig. 2H), yet IL-12p40 production was significantly augmented over pDC (p<0.0001, Fig. 2H). To test their ability to expand T lymphocytes in culture, sorted B-pDCs and pDCs were incubated with CpG:ODNs and co-cultured with freshly isolated CFSE-labeled lymphocytes. After 6 days, co-cultures were stained for CD3 and CFSE-negative cell percentages were recorded (Fig. 2I-J). Although further studies will be required to elucidate the effects of TLR7 engagement in B-pDCs, our results showed B-pDCs were significantly better at expanding T cells in co-cultures than conventional pDCs (p=0.02, Fig. 2I-J) upon TLR9 activation.

To further elucidate their phenotype at the genetic level, we performed RNA-seq analyses of purified B-pDCs and compared them to classical, myeloid-derived bulk pDCs. Expression of hallmark pDC genes was confirmed by RT-PCR of shared pDC markers (Fig. S3A). While the overall gene expression patterns were highly similar across the two subsets, ~1% of transcripts (~220 genes) differed significantly (q value< 0.05) (Fig. S3B). Among the top overexpressed genes in B-pDCs were Lyz1, Ccr3, Cd86, Id2, Axl, Siglec1, and Cd81 (Fig. S3C). Differentially expressed transcripts generated Gene Ontology (GO) or Panther terms including “immune response”, “inflammatory response”, “cell activation”, and “regulation of immune response” (p=1.36x10^{-17}, 2.15x10^{-12}, 3.67x10^{-11}, and 1.45x10^{-10}, respectively (Fig. S3C). Gene set enrichment analysis (GSEA) revealed elevation of each of these same GO/Panther terms within the B-pDC subset as compared to a pDC-related GSEA control dataset that showed no enrichment. Next, we compared all genes expressed by both pDC populations to one another and to published RNA-seq of BM-derived mouse pre-B cells (B220^{+} IgM^{-} Kit^{+} CD25^{+})—a post-CLP B cell progenitor (pre-B) population. As shown in Figure S3D, pDCs and B-pDCs expression levels were strongly correlated to one another.
relative to early B cells (R² values = 0.8959, 0.4145, and 0.404, respectively) (Fig.S3D).
Collectively, these data support our contention that B-pDCs are functionally distinct from classical pDCs and specialize in inflammatory responses, antigen presentation, and T cell activation.

AXL⁺ transitional DCs (tDCs or AS-DCs)¹,⁵⁷ have been identified in humans by the high expression levels of the genes AXL, CD81, CD86, LYZ2, C1QA, CD2, and C1QB relative to classical pDCs ¹⁻⁴. They also exhibit many classical pDC features, having previously been described phenotypically as a “continuum” between pDC and cDC2 populations ². In order to confirm AXL⁺ pDCs are also present in mice and corroborate our RNA-seq findings, we phenotyped B-pDCs through imaging flow cytometry. First, we again verified that our primary gating scheme effectively encompassed bona-fide pDCs using imaging flow cytometry. As expected, B220⁺ PDCA1⁻ cells were >95% CD19⁺ SIGLEC-H⁻ (B cells). Most importantly, >95% of B220⁺ PDCA1 hi cells were SIGLEC-H⁺ and CD19⁻, ruling out any pDC population contamination (Fig. S.4A-B). At the protein level, we were able to stain mouse BM cells with anti-AXL antibodies without issues and confirmed that while ~60% of B-pDCs were positive for AXL, only ~10% of YFP negative pDCs expressed this protein (Fig. S4A, C-E). Finally, imaging of BM cells showed that B-pDCs resembled classical secretory pDCs morphologically, presenting a large nucleus and defined plasma-like features, in contrast to B cells (Fig. S4A).

This preliminary phenotypic analysis led us to speculate that similarly to human AXL⁺ transitional DCs, B-pDC might also prioritize their secretory capacity for copious transcription and secretion of alternative immune system modulators. Thus, we performed high resolution 10x single cell RNA-seq analyses of magnetically sorted PDCA1⁺ bone marrow
cells (96% purity as determined by flow cytometry) and compared the B-pDC transcriptional profile to that of other pDCs. Principal component-based clustering and UMAP visualization of sorted PDCA^+ cells yielded 22 discrete clusters. To identify cell populations in an unbiased manner, we uploaded the top 1000 differentially expressed genes (DEGs) from each cluster into CIPR (Cluster Identity Predictor)\(^6\), which uses the reference database ImmGen (mouse) to calculate cell identity scores (S. Table 1). Seurat clusters were named according to the consensus of the top 5 cell ID hits generated by CIPR (Fig. 3A). We confirmed CIPR assignments by evaluating cluster DEGs and expression of markers associated with specific myeloid cell populations (Fig. S5). PDCA^+ cells comprised 9 distinct pDC populations (including B-pDCs, which were unanimously identified as pDCs by the top CIPR identity scores). A small B cell cluster (3.01% of all cells analyzed) expressing low levels of Bst2 (PDCA1 gene), as well as distinct subpopulations of macrophages (Mac1, 2, and 3), monocytes (Mono1, 2 and 3), and granulocytes (Granul1, 2, and 3) were also identified. Two stem-progenitor populations (Prog1 and 2) were present in our cell pool (1.12% and 2.86% of cells analyzed, respectively) (Fig. 3A-B). The heterogeneous Prog2 population expressed high levels of genes associated with pDCs, including Siglech, Bst2, Flt3, TCF4, and Irf8 (Fig. S5, S. Table 2). In addition, the majority of cells in the Prog2 cluster were Csf1r^− Siglech^−, Ly6d^+ (Fig. S5, S. Table 2 and not shown), resembling the pro-pDC myeloid precursor population described by Feng and colleagues\(^5\). In contrast, Prog1 (which clustered near B cells) expressed several pre/pro B cell genes, including Jchain, Igcl1, Igcl2, Igha, Igkc (S. Table 2). Direct DEG comparison between Prog1 and Prog2 clusters confirmed Prog1 cells exhibit a more “Pre/Pro B cell-like” developmental profile and low expression of markers that are “pDC biased” relative to Prog2. (S. Table 2). After clustering and profiling PDCA^+ cells, we subset
the data in order to compare B-pDCs gene expression to only B cell and pDC clusters using Wilcoxin rank sum tests. We plotted several genes commonly associated with B cells, and pDCs. Expression of canonical pDC genes was present but reduced in B-pDCs relative to classical pDC subsets (Fig. 3D). Except for $Cd79a$ ($Mb1$) and $Cd79b$, B-pDCs showed negligible expression of mature B cell associated genes such as $Pax5$, $Cd19$ and $Cd22$ (Fig. 3C). In the context of markers associated with $AXL^+$ transitional human DCs, the clusters B-pDCs, pDC5, and pDC7 (a small, highly heterogeneous cluster that included a subpopulation of cells expressing $Hbb$ genes) expressed the highest levels of $Axl$, $Lyz2$, $Cd81$, $C1qa$, and $C1qb$ (Fig. 4A). $Cd81$ expression in B-pDCs was higher than in other pDC subsets (Fig. 4A). Of note, $Cd81$ and $C1qb$ have been described as hallmark genes of a discrete mouse pDC population that does not produce type I IFN and yet mediates important immune functions previously attributed to all pDCs$^2,37$. Overall, our single-cell RNA seq analysis revealed that although B- pDCs resemble non-canonical $AXL^+$ transitional human DCs in function and transcriptional profile, they are not the only pDC subset that presents an intrinsically “activated” phenotype among murine pDC subsets. In accordance, subsetting our dataset into only Axl high pDC clusters revealed the heterogeneity within and among $AXL^+$ murine pDC populations. Surprisingly, with exception to $Axl$, $Cd81$, $Lyz2$, and $Ly6$ family members, the number of reads for multiple myeloid markers previously used to line up transitional and non-canonical murine DCs to human $AXL^+$ DCs via CyTOF or bulk RNA-seq$^1,57$ (e.g. $Irf4$, $Csf1r$, $Id2$, $Itgax$, $Cd2$, $Cd5$, $Cx3cr1$, $Cd33$) were negligible or low in both $Axl^+$ and $Axl^-$ murine pDC clusters (Fig. 4B and not shown), potentially due to more stringent gating schemes or parameters used by other groups to define and purify dendritic cells. Altogether, this data shows that constitutive expression of $Axl$ and innate activation markers are present in more
than one transcriptionally distinct murine pDC profile, highlighting the functional heterogeneity and plasticity of both lymphoid and myeloid derived murine pDCs.

Pseudotime is a measure of how much progress an individual cell has made through a process such as differentiation\textsuperscript{59, 60}. In other words, cells that belong to a single cluster can be segregated across various transcriptional “states” based on number of reads per cell of a particular set of developmental genes. Although we cannot definitely say the pre/pro B cell-like Prog1 cluster represents an immediately adjacent common progenitor for B cells and B-pDCs, we confirmed B-pDCs are not a precursor for B cells based on their single cell developmental trajectory. We used Prog1 cluster (identified as a Multi-lymphoid Progenitor by CIPR) as state “0” (Fig. 5A) based on their abundant expression of lymphoid progenitor genes. Analysis of uniquely expressed genes showed Prog1 downregulated several multipotency markers such as \textit{Stmn1}, \textit{Gata2}, and \textit{Ctla2a}, while B cells increased expression of transcription factors needed for B cell commitment (e.g., \textit{Pax5}, \textit{Ebf1}, and \textit{Ms4a1}) (Fig. 5B and 5C).

Although B-pDCs did not express detectable levels of most B cell commitment markers evaluated, they did retain expression of early B cell receptor associated genes, including \textit{Ly6D}, \textit{Ighm}, \textit{Igkc}, \textit{Iglc2}, and \textit{J Chain} (Fig. S6A). Of note, we were unable to detect these early B cell markers in B-pDCs via flow cytometry (not shown), probably because their protein expression levels were low. Additionally, since these early B cell related markers are also expressed in plasma cells, we performed flow cytometric analysis of B220\textsuperscript{+} PDCA1\textsuperscript{+}: CD79a\textsuperscript{+} cells. We discovered that while B-pDCs express negligible levels of TACI (a transcription factor that silences the B-cell developmental program\textsuperscript{62} and that expression of CD138 and IgG1 was also negligible (Fig. S6B, and not shown), ruling out any major plasma cell overlap at the protein level. Lineage analysis also revealed that B- pDCs enhanced expression of the pDC associated
markers Siglec, Tcf4, Bst2, and also of Xbp1 (a marker expressed at high levels in secretory cells). Committed B cells in turn downregulated these markers as they progressed through pseudotime (Fig. 5D). In summary, lineage analyses revealed B-pDC are a discrete population of CLP-derived pDCs that retain expression of early B cell receptor genes but lack expression of many transcription factors required for ultimate B cell lineage commitment.

Both pDCs and B cells require BCL11A for their development and exhibit gene expression overlap between the two lineages\textsuperscript{14}. This suggested that pDC and B cells may share transcriptional control mechanisms downstream of BCL11A. To test this hypothesis, we employed ChIP-seq in model human cell lines to compare direct BCL11A chromatin-bound target genes and how these gene sets might differ between a pDC line (CAL1) and model B cell lines: (1) the human pre-B cell line NALM6; (2) the human germinal center Burkitt’s lymphoma B cell line RAJI; and (3) the murine lymphoblastoid B cell line, GM12878\textsuperscript{38}. CAL1 expresses classical pDC markers\textsuperscript{9,39} as well as significantly upregulated levels of Axl expression\textsuperscript{40}. CAL1 was derived from a patient with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and deadly malignancy that uniformly expresses high levels of BCL11A and which, although its ontogeny is unclear, is widely believed to originate from pDCs\textsuperscript{9,41,42}. Indeed, single-cell analysis has confirmed that whereas primary BPDCN malignant cells express several key B cell markers (\textit{IGLL1, IGLL5, SPIB}) they are most closely related to pDCs and AXL\textsuperscript{+} transitional DCs\textsuperscript{1} (Fig. S7A). The occupancy pattern of BCL11A in CAL1 pDC bore a striking resemblance to its binding distribution in the three human B cell types, with nearly a quarter of all CAL1 targets shared among all B cell lines (Fig. S7B). Curiously, these included BCL11A occupancy on its own promoter region in each cell line. In contrast, while B cells and pDC share numerous BCL11A targets, others are bound
in a cell context-dependent fashion, including B cell-only binding in *PAX5*, *TCF3*, and *ID3* loci; CAL1 only binding in *AXL*, *SIGLEC1*, and *IGLL1*; and binding across cell types but with non-overlapping peaks in *SPIB* and *ID2*. Our ChIP-seq analysis of genome-wide BCL11A target binding in multiple human cell lines suggests that an evolutionarily conserved transcriptional hierarchy might in fact distinguish B-pDC and B cells in both humans and mice.

**Discussion**

Dendritic cell–subset biology, development, and the ensuing nomenclature have long been unclear and everchanging. Here, we provide definitive evidence in support of the long-suspected “lymphoid past” of pDCs by establishing their ability to arise *in vivo* from CLP progenitors with B/pDC bipotential lineage capacity. Our data suggest that the murine pDC compartment is bipartite, being comprised of B-pDCs—diverted from the CLP post T-B bifurcation—as well as myeloid-derived classical pDCs. Unlike most myeloid derived pDCs, B- pDCs constitutively express high levels of multiple innate activation markers, including *C1qa, C1qb* and *Lyz2*. Functionally, they expand more readily after TLR9 engagement than classical pDCs and excel at activating T cells in culture. While further functional definition awaits discovery, our work provides a framework for the identification and segregation of the B-pDC lineage (comprising almost 1/5 of the total pDC compartment) from other myeloid-derived pDC subpopulations. Primarily, our observations support the hypothesis that DCs functionality derive primarily from ontogeny rather than from tissue environment, exemplified by evolution of a specialized pDC lineage from a lymphoid progenitor. In the case of the B-pDCs, our data suggest such a cell should exist within the late CLP, and may deviate from B cell commitment after *Ly6d* expression, thought to be the earliest marker of B cell
specification\textsuperscript{26}. Most noticeably, our newly described B-pDC population expresses high levels of the tyrosine kinase AXL and specializes in T cell activation through displaying high levels of MHC II and costimulatory markers such as CD81 and CD86. Interestingly, Axl\textsuperscript{a} ablation in mice has previously been shown to increase expression of type I IFN while impairing IL-1\beta production and T cell activation during viral infections \textsuperscript{63,64}. In conjunction to describing a novel B cell-like pDC population, we profiled PDCA1\textsuperscript{+} pDCs and established that the murine AXL\textsuperscript{\textsuperscript{+}} pDC compartment is highly transcriptionally heterogeneous, clustering based on expression of genes associated with early B cell development or antigen presentation. In light of these findings, it is likely that the AXL\textsuperscript{+} B-pDCs share an important role with AXL\textsuperscript{+} myeloid derived pDCs in pushing forward T cell expansion while curbing innate immune responses that can result in autoimmune damage. The demarcation of lymphoid derived B- pDCs as one of the three AXL\textsuperscript{+} pDC subsets found in mice may help clarify the perceived plasticity of the pDC compartment in normal and disease contexts\textsuperscript{51}, as well as provide a new cell for targeted study within the context of autoimmune disease, cancer, and infection models.
Figure 1. Mb1-Cre deletion of Bcl11a identifies a CLP-derived subset of pDCs

(A) Representative FACS plots of pDC (gated as B220⁺ PDCA1⁺) and B cell (gated as B220⁺ PDCA1⁻) percentages in the bone marrow (BM) of Bcl11a°F/F mb1-Cre mice (cKO) and littermate controls. (B) Quantification of pDC and B cell populations in the BM of Bcl11a°F/F mb1-Cre mice (cKO) and littermate controls as cells/100,000 cells. (C-D) Flow cytometric analysis of BM and spleens of recipient mice 8 weeks post BM transplantation. BM was transferred from either BCL11A-sufficient reporter control mice (mb1-Cre-YFP) or BCL11A-deficient cKO mice (Bcl11a°F/F mb1-Cre-YFP) into lethally irradiated C57BL/6J recipients. (E) B cell numbers after BM transplantation in BM and spleens of recipient mice. (F) pDC numbers after BM transplantation in BM and spleens of recipient mice. (G) Comparison of YFP⁺ pDC percentages in the spleen and BM of recipient mice post BM transplantation. Student’s t-test was used for all statistical comparisons (n=6 mice).

Figure 2. CLP-derived B-pDC are licensed for T cell activation

(A-B) Comparison of MHCII MFI in YFP⁺ and YFP⁻ pDCs from Mb1-Cre-YFP reporter mice via flow cytometric analysis. (C-D) Mb1-Cre-YFP mice were injected with 50 ug/ml (100 ul) of CpG:ODN or control GpC:ODN and analyzed via flow cytometry for splenic pDC numbers/100,000 cells (***p<0.0001). (E) Flow cytometry quantification of YFP⁺ pDC and B-pDCs (YFP⁺) fold change in cell numbers upon CpG:ODN in vivo challenge (**p=0.002142 for YFP negative pDC expansion; ***p= 0.00023 for B- pDC expansion, and *p=0.0151 for Cpg stimulated YFP⁺ and YFP- pDC number comparison). (F-G) pDCs expressed higher levels of CD86 and CD83 once restimulated in vitro with CpG:ODN (green=YFP⁺, black=YFP⁻) (H) In vitro TLR9 engagement of B-pDC or pDC for ELISA against IFN-α or IL-
12p40. (**p<0.0001). (I) CD3+ T cell expansion of CFSE-labeled murine lymphocytes (2.5x10^4) cultured alone or with CpG:ODN activated B- pDCs or pDCs (5x10^3) in triplicates for 6 d. Representative plots shown. (J) The percentage of CFSE- negative CD3+ T cells in cocultures were significantly higher in B-pDC compared to pDC (p>0.0001). Student’s t-test was used for all statistical comparisons.

**Figure 3. Single cell RNA-seq analysis of mouse PDCA1+ bone marrow cells**

(A) UMAP generated by Seurat clustering analysis. Cluster identities were assigned using the top 5 consensus CIPR identity scores. (B) Heatmap of the top 5 DEGs from each cluster. After Seurat clustering, cell reads were subset to include only cells classified as B cells, pDCs, and B- pDCs. DEGS were generated for the new data subset and markers associated with mature B cells (C) classical pDCs were plotted as violin plots.

**Figure 4. Transcriptional heterogeneity of Axl+ murine pDC populations.** (A) Violin plots depicting relative expression of “non canonical AXL+ DCs” associated markers in mouse pDC clusters. (B) Dot plot depicting expression prevalence of select “AXL+ DC” associated markers and pDC DEGs (ranked by p value) for pDC1 and 3 homogeneous mouse Axl+ pDC populations.

**Figure 5. Single cell trajectory analysis of Prog1, B cells, and B-pDC clusters**

(A) Single cells belonging to clusters Prog1, B cells, and B-pDCs were ordered and plotted as a function of pseudotime based on uniquely expressed markers using the unsupervised Monocle dpFeature. Cluster Prog1 was classified as the root of the trajectory given its high expression of pre-pro B cell and stem cell associated markers. DEGs of interest were plotted as a function of pseudotime in Prog1 (B), B cells (C), or pDCs (D) using Monocle. Branch Y_112 represents
the expression kinetic trend of the B-pDC cluster (green), while branch Y_83 represents the expression kinetic trend in expression of B cells according to branched expression analysis modeling, or BEAM.

**Supplemental Figure Legends**

**Supplemental Figure 1. Progenitor population analysis for mb1-cre driven YFP expression.** We analyzed YFP expression in BM progenitors to determine when and where mb1-Cre is active (representative plots shown). (A) Lineage negative cells were analyzed to examine LSK Hematopoietic progenitor (Lin\(^-\), Sca-1\(^+\), c-Kit\(^+\)), MPP (LSK, Flt3\(^{int}\)), and LMPP (LSK, Flt3\(^{hi}\)) populations. Virtually all cells were YFP\(^-\). (B) Myeloid Dendritic Progenitors (MDP; Lin\(^-\), IL7R\(\alpha\)-, Flt3\(^+\), c-kit\(^{hi}\), Sca1\(^-\)) and (C) Common Dendritic Cell Progenitors (CDP; Lin\(^-\), IL7Ra-, Flt3\(^+\), c- kit\(^{lo}\), Sca1-, CD115\(^+\)) were also negative for YFP expression, while (D) Common Lymphoid Progenitors (CLP; Lin\(^-\), IL7Ra\(^+\), Flt3\(^+\), c- kit\(^{lo}\), Sca1\(^{lo}\)) contained YFP\(^+\) cells.

**Supplemental Figure 2. Cell distributions in the spleen of adoptively transferred recipient mice.** (A) Both Bcl11a\(^{F/F}\) mb1-Cre\(^+\) and Mb1-Cre-YFP adoptively transferred recipient mice reconstituted other splenic cell types in normal numbers, including BM macrophages (CD11b\(^+\) F4/80\(^+\)), granulocytes (Gr-1\(^+\) CD11b\(^+\)) and splenic cDCs (CD11c\(^+\) CD11b\(^+\) B220\(^-\)). Total T cells (CD3\(^+\) B220\(^-\)) as well as CD4\(^+\) and CD8\(^+\) subsets were significantly increased in number in proportion to B/pDC cell loss. Student’s t-test was used for all statistical comparisons. (B) Representative gating scheme for T cells cocultured for 6 days with sorted YFP\(^-\) pDCs or mb1-YFP\(^+\) B-pDCs.
Supplemental Figure 3. Transcriptional analysis identifies two populations of pDC in mice: myeloid-derived classical pDC and CLP-derived B-pDC. (A) Bone marrow pDC (B220+ PDCA1+ CD11cint CD11b-) were sorted based on expression of YFP. Four mice were pooled for each isolated RNA sample, for a total of three pDC and three B-pDC groups from 12 mice. RT-PCR was used to confirm that Bcl11a, Bst2, SpiC, and Id2 expression match RNA-seq trends between pDC and B-pDC (B) RNA-seq was performed for gene expression analysis of pDC vs B-pDC and 220/23,946 genes (~1%, left) were significantly differentially expressed (q value < 0.05, right heatmap, Log2 expression difference displayed). (C) Gene Set Enrichment Analysis (GSEA). Normalized enrichment score (NES) and false discovery rate q-values (FDR); FDR ≤ 0.25 is considered significant. GO Term or Panther-derived pathways identified by DAVID analysis of ~220 differentially expressed genes between the pDC and B-pDC subsets. Among the top B-pDC DEGs were Lyz1, Ccr3, Cd86, Cd83, Id2, Axl, Siglec1, and Cd81. (D) Scatter plot comparisons of all genes with Reads Per Kilobase of transcript, per Million mapped reads (RPKM) >1. Correlations of pDC vs B-pDC (R2 value = 0.8959), B cell vs. pDC R2 value = 0.4145) and B cell vs. B-pDC (R2 value = 0.404) are indicated.

Supplemental Figure 4. Imaging flow cytometry as a tool to quantify AXL expression in pDC populations. (A-B) Representative Imaging flow cytometry of manuscript gating scheme used to define B cells and pDCs and histograms for SIGLEC-H, AXL and CD19 in B cells and pDCs (C) Representative Imaging flow cytometry plots of AXL+ pDCs (here alternatively gated as SIGLEC-H+ PDCA1+) in Mb1-Cre-YFP reporter mice bone marrow cells (n=6). (D) Complete statistics table generated with IDEAS for Image Stream analysis including non-stained wildtype controls. (E) Comparison of AXL expression in YFP+ and YFP+ (B-pDCs) (p<0.0001, unpaired T tests).
Supplemental Figure 5. Confirmation of unbiasedly identified cell cluster identities.

Seurat generated violin plots of genes associated with distinct cell populations including mature B cells, pDCs, granulocytes, pre-pDCs, NK cells, monocytes, macrophages, and myeloid progenitor cells. Plot identities were initially determined by running the package CIPR (Cluster Identity PRedictor).

Supplemental Figure 6. Expression of early B cell receptor genes in B-pDCs. (a) Monocle was used to plot select early B cell genes as function of branched pseudotime for Prog1, B Cells, and B-pDC populations. (b) Plasma cell contamination in $Mb1^+$ pDCs ($B220^+\ PDCA1^+$) was ruled out by flow cytometric analysis of TACI and CD138 in BM of 4 C57BL/6J mice.

Supplemental Figure 7. ChIP-seq analysis of genome-wide BCL11A target binding in multiple human cell lines underscores an evolutionarily conserved transcriptional hierarchy distinguishing B-pDC and B cells in both humans and mice. ChIP-seq for BCL11A was performed in the human pre-B cell line NALM6 (green) and the human Burkitt’s lymphoma line RAJI (black) and was compared to ChIP-seq acquired in the human pDC model cell-line CAL1 (blue) and the ENCODE consortium acquired ChIP-seq of the human B lymphoblastoid cell line GM12878 (red, all peak scores $\geq 10$). (A) Overlap of BCL11A target genes between the four cell lines. A target gene was defined by a binding site occurring within 50 kb upstream through the intron of that gene. Analysis of the false discovery rate and associated q-values were performed using Benjamini–Hochberg statistics. (B) Selected overlapping and differentially bound targets in B and pDC lines (peak scores $\geq 10$).
Supplemental Table 1. Top CIPR Assigned Identity Scores for Seurat Cluster DEGs.

CIPR IDs were generated using the top 1000 DEGS from each cluster. The top 5 consensus CIPR ID generated was used to rename Seurat clusters.

Supplemental Table 2. DEG comparison between progenitor clusters.

The top 50 differentially expressed features of Prog1 in relation to Prog2 were calculated using Seurat using non-parametric Wilcoxon rank sum test. In blue are upregulated genes and in red are downregulated genes.

Methods

Mice

Generation of Bcl11a cKO Mice (C57BL/6J background) was performed as described\textsuperscript{14}. To generate conditional knockouts for the Mb1 gene, specifically, Bcl11a\textsuperscript{F/F} mice were crossed to Mb1-Cre\textsuperscript{+} Rosa26-YFP\textsuperscript{+} reporter mice. Mb1-Cre deleter and Rosa26- YFP reporter strains (C57BL/6J genetic background) were obtained from Jackson labs (catalog #’s 020505 and 006148, respectively), bred, and genotyped according to the vendor protocol and their validated primers. All housing, husbandry, and experimental procedures with mice were approved by the Institutional Animal Care and Use Committees at the University of Texas at Austin. 6-week-old gender matched male or female mice were used for all experiments described in this manuscript.

Tissue processing

Mouse femurs were cut at the extremities and a 25G needle was inserted in the bones to flush out bone marrow cells with 10 ml of cold PBS onto a 70 uM strainer in a 50 mL tube. Cells
were washed from the strainers into the tubes with an additional 10 mL of PBS. Tubes were spun at 300G for 5 minutes and supernatant was decanted. 2 mL of ACK red blood cell lysis buffer was used to resuspend cells, which were incubated for 2 minutes and 20 seconds. Samples were diluted with 20 mL of cold PBS, washed once, re-filtered and resuspended in 200 uL of FACS buffer for subsequential flow cytometry staining. Spleens were mashed onto pre-wet 70 uM filters in a 50 mL tube with syringe plungers and 20 mL of cold PBS was added through the strainers into the tube. Cells were spun at 300G for 5 minutes and supernatant was decanted. 2 mL of ACK red blood cell lysis buffer was used to resuspend cells, which were incubated for 2 minutes and 20 seconds. Samples were diluted with 20 mL of cold PBS, washed once, re-filtered and resuspended in 200 uL of FACS buffer for subsequential flow cytometry staining.

Flow cytometry

Single cell suspensions (1x10^6 cells) were resuspended in 200 uL of FACS buffer (5 mM EDTA and 1% Heat Inactivated Fetal Calf Serum in D-PBS) and incubated for 15 minutes with surface antibody cocktail (each antibody at a concentration of 1.25 micrograms/ml in FACS buffer) in the dark at 4°C. Cells were then washed 3 times with FACS buffer and ran live on a BD LSRII Fortessa. For intracellular staining, cells were fixed for 45 minutes at 4°C following the eBioscience Foxp3 buffer fixation protocol. Cells were intracellularly stained using 1x Perm buffer (eBioscience) containing dye-antibody conjugates (2.5 microgram/ml per antibody) for 45 minutes. Cells were washed 3 times with 1x Perm buffer and then twice more with FACS buffer. Single color controls for panel compensation were made using AbC Total Antibody Compensation Bead kit (ThermoFisher Scientific), by staining each control with one of the panel antibodies and using these controls to compensate the flow cytometer experiment prior to
running the samples. A non-stained sample of cells was included in experimental runs and used to adjust for autofluorescence and any nonspecific staining. FMO single cell controls were also included in some of the experimental runs (cells stained with all antibodies in the panel minus one), for compensation quality control and to detect positive MFI thresholds for each fluorophore using cells. Sorting was performed on a FACS Aria (BD Biosciences). All analysis was done using FlowJo (Tree Star) software. Single-cell suspensions were stained with the following antigen-specific monoclonal antibodies (clones in parenthesis): anti CD45R/B220-BV605 (RA3- 6B2), CD19-Alexa Fluor 700 (6D5), CD86-APC-Cy7 (GL-1), I-A/I-E-Pacific Blue (M5/114.15.2), IL7R-BV421 (A7R34), cKit-PE-Cy7 (ACK2), CD11b-PerCP-Cy5.5 (M1/70), CD3e-PerCP-Cy5.5 (500A2), Gr1-PerCP-Cy5.5 (RB6-8C5), CD4-PerCP-Cy5.5 (RM4-5), CD8-PerCP-Cy5.5 (53-6.7), NK1.1-PerCp- Cy5.5 (PK136), Sca1-BV711 (D7), CD135-APC (A2F10), CD150- BV605 (TC15-12F12.2), Siglec1-PE-Cy7 (3D6.112) (all Biolegend), CD79a-FITC (24C2.5) (Invitrogen), Anti-CD11c-PerCP-Cy5.5 (N418) (eBioscience), Anti-AXL-APC (175128)(R&D Systems), Anti-CD23 BV510 (B3B4) (Biolegend), Anti-CD267-BV421 (8F10) (BD Biosciences), Anti-CD138-APC (281-2) (Biolegend), and Anti-PDCA1-PE or Biotin (JF05-1C2.4.1) (Miltenyi Biotech), in D-PBS/2% (vol/vol) FBS FACS buffer. In some experiments, viability stain Ghost Dye Red 780 (Fisher Scientific) was used to stain cells in PBS prior to antibody staining according to the manufacturer’s protocol. Flow cytometry data was analyzed with FlowJo, while Imaging flow cytometry was performed on ImageStream X and analyzed on IDEAS® 6.0 (Amnis), by pre-filtering out of focus cells and performing automatic software guided compensation with single color controls.

Bone Marrow Transplantation
Bone marrow from 6-week-old $Bcl11a^{F/F}/mb1-Cre^{+}$ cKO or Mb-1-Cre-YFP reporter mice (n=3 per group) were collected from femurs and 5x10^6 bone marrow cells were transferred via retro-orbital injection into recipient immunocompetent C57BL/6J mice lethally irradiated with two doses of 450 rad 1 hour apart. Mice were kept on an antibiotic diet for 3 weeks to allow for immune reconstitution. Eight weeks post transfer, mice were sacrificed and cells collected from BM and spleen to investigate reconstitution of cellular subsets.

RNA isolation and RNA-seq

For sorting prior to RNA collection, BM from 12 mice was prepared from femurs at 6 weeks of age, combined into three groups (4 mice/group). Total RNA was extracted from FACS sorted $Bcl11a$ cKO BM pDCs (approximately 100K YFP$^+$ pDCs and 400K YFP$^-$ pDCs per pooled sample) using TRIzol reagent (Invitrogen). Taq polymerase (New England Biolabs) and a Perkin-Elmer 2700 thermocycler were used to amplify transcripts for the following mouse genes: $Bcl11a$ (F: 5’-GTGGATAAAGCCGCCTCCCCCTT-3’, R: 5’-GGGGACTTCCGTGTTAGCTAAGCTC-3’), $Bst2$ (F:5’- AGGCAAACTCCTTGCAACCTG-3’, R: 5’-ACCTGCACTGTGTAGCTAAGCTC-3’), $SpiC$ (F: 5’-ATCCTCAAGTCAAGGCAC-3’, R: 5’-TGTACGGATTGGTGAAGCC-3’), $ld2$ (F: 5’-GGACATCAGCATCCTGTCCTTGC-3’ R: 5’-TGTACGGATTGGTGAAGCC-3’), and $\beta$-actin (F:5’AGGTGTGATGGTGGGAAT-3’, R: 5’-GGTGTAACGCAGCTCAGT-3’) and probe RNA sequencing potential. For bulk RNA-seq, twelve mice were pooled into three YFP$^+$ groups, and total RNA was extracted as above. Oligo-dT-primed cDNA was prepared using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). Poly(A) mRNA was enriched using the NEBNext magnetic isolation module (E7490) and samples underwent DNAse treatment. cDNA was prepared using the Ultra Low kit from Clontech (Mountain
Libraries were prepared at the according to manufacturer’s instructions for the NEBNext Ultra II Direction RNA kit (NEB, product number E7760). The resulting libraries tagged with unique dual indices were checked for size and quality using the Agilent High Sensitivity DNA Kit (Agilent). Library concentrations were measured using the KAPA SYBR Fast qPCR kit and loaded for sequencing on the Illumina NovaSeq 6000 instrument (paired-end 2X150, or single-end, 100 cycles; 30x10^6 reads/sample). Data were analyzed using a high-throughput next-generation sequencing analysis pipeline: FASTQ files were aligned to the mouse genome (mm9, NCBI Build 37) using TopHat2. Gene expression profiles for the individual samples were calculated with Cufflinks as RPKM values. YFP+ pDC samples were normalized to each control YFP- pDC sample. GO terms identified as significantly different: GO:0006955, GO:0009611, GO:0048584, GO:0006954, GO:0002684, GO:0001775, GO:0009986. Panther terms: BP00148, BP00155, BP00102, BP00120. Gene Set Enrichment Analysis (GSEA) using ordered gene expression levels of Common Lymphoid Progenitor-derived B-pDC and Common Myeloid Progenitor-derived pDC were significantly enriched in both GO terms and Panther-derived gene sets. A randomly selected control GSEA curated set, GSE7831: UNSTIM_VS_INFLUENZA_STIM_PDC_4H_DN (defined as genes down-regulated in untreated pDC versus influenza virus infected pDC 55 showed insignificant enrichment. Normalized enrichment score (NES) and false discovery rate q-values (FDR); FDR ≤ 0.25 is considered significant.

TLR9 engagement

Mb1-cre-YFP reporter mice were injected via tail veins with 100ul of PBS containing 50ug of CpG:ODN (n=4) or GpC:ODN control (n=4) (CpG-B no.1826, TCCAT GACG TTCCT GACGTT; control non-CpG-B no.2138, TCCATGAGCTTCTGAGCTT,
Invivogen, USA). At 24 hours, mice were sacrificed and bone marrow and spleens were collected for pDC phenotyping.

Cell co-cultures

Mb1-YFP+ B-pDC (B220+ PDCA1+ YFP+) and Mb1-YFP+ pDCs (B220+PDCA1+YFP+) subsets were sorted on a FACS Aria (BD Biosciences) by and cultured in 96-well round bottom plates with RPMI medium 1640 containing 10% (vol/vol) FBS, 2 mM L-glutamine, 100 units/mL penicillin and streptomycin, 1 mM sodium pyruvate, and 10 mM Hepes, and with or without 5 μg/ml class A CpGs (ODN 1585, InvivoGen) for 24 hours. pDCs were then washed three times to remove residual CpG. Preactivated pDCs (5 × 10^3) were cultured with CFSE-labeled lymphocytes (2.5 × 10^4) magnetically sorted using MACs columns from mouse spleens for a total of 6d with 20 units/mL of IL-2. CSFE labelling of lymphocytes (for which sorting purity was determined to be 97% via flow cytometry) prior to coculturing experiment was done using the CellTrace™ CFSE Cell Proliferation Kit (ThermoFisher Scientific) accordingly the manufacturer’s protocol.

Enzyme-linked immunosorbent assays (ELISA).

Sorted B-pDC and pDCs (5 × 10^3 sorted cells per well, n= 3 per group, done in duplicate wells for each condition) were stimulated with 5 μM CpG-A (ODN 1585, Invivogen) or CpG-C (ODN 2395, Invivogen); or left untreated for 24 hs. ELISAs for IFN-α (Invitrogen) or IL-12p40 (BioLegend), respectively, was performed in 100 uL of cell free supernatants according to manufacturer’s instructions. Data was acquired using a Bio-Tek model EL311 automated microplate reader measuring absorbance at 450 nm.
Statistical analysis

All flow cytometry or ELISA data were analyzed with Prism (Version 8; GraphPad, La Jolla, CA) using Student’s t-test. All bar graphs show means and standard deviation (SD) and are representative of repeated experiments. These data were considered statistically significant when \( P \)-values were <0.05.

ChIP followed by ChIP-seq

ChIP assays for BCL11A were performed and analyzed as described\textsuperscript{14}. ChIP-seq data was analyzed by deep sequencing using Illumina sequencing technology as described above. ChIP-seq for BCL11A was performed in the human pre-B cell line NALM6 (green) and the human Burkitt’s lymphoma line RAJI (black) and was compared to ChIP-seq acquired in the human pDC model cell-line CAL1 (blue) and the ENCODE consortium acquired ChIP-seq of the human B lymphoblastoid cell line GM12878 (red, all peak scores ≥ 10). Overlap of BCL11A target genes between the four cell lines. A target gene was defined by a binding site occurring within 50 kb upstream through the intron of that gene. Analysis of the false discovery rate and associated q-values were performed using Benjamini–Hochberg statistics. Selected overlapping and differentially bound targets in B and pDC lines (peak scores ≥ 10).

10x Single cell RNA-seq analysis

PDCA1\textsuperscript{+} C57BL/6J bone marrow cells from 4 pooled 6 week old wildtype C57BL/6J mice were magnetically sorted using MACS columns into culture medium, washed once with PBS \textsuperscript{+} 0.04% BSA, and re-suspended in 32 µl PBS \textsuperscript{+} 0.04% BSA. Single cell suspensions (50,000) were processed in the University of Texas Genomic Sequencing and Analysis Facility. Cell suspensions were loaded on the Chromium Controller (10X Genomics) and processed for
cDNA library generation following the manufacturer’s instructions for the Chromium NextGEM Single Cell 3’ Reagent Kit v3.1 (10X Genomics). The resulting libraries were examined for size and quality using the Bioanalyzer High Sensitivity DNA Kit (Agilent) and their concentrations were measured using the KAPA SYBR Fast qPCR kit (Roche). Samples were sequenced on the NovaSeq 6000 instrument (paired end, read 1: 28 cycles, read 2: 90 cycles) with a targeted depth of 71,130 reads/cell. Cellranger (v3.0.2) was used to demultiplex samples, to map data to the mouse transcriptome (mm10) and quantify genes. The gene counts matrix was read into Seurat (v3.2.1). Cells with unique feature counts over 3,500 or less than 200, and >3% mitochondrial read counts were removed from the analysis. The data was normalized and transformed using scTransform. Cells were clustered based on the top 1000 variable features, 20 PCs, and a resolution of 0.6 (Seurat's graph-based clustering approach), and then visualized using UMAP. Analysis of the normalized and filtered single cell gene expression data (median of 2,423 genes across 4,206 single-cell transcriptomes) was used for the final expression table and downstream analysis. Wilcoxin rank sum test was used to test for differential expression among clusters and identify gene markers (logfc.threshold = -1, min.pct = 0.25). Gene markers and other genes of interest were visualized using violin plots and heatmap plots. Unsupervised ordering of PDCA1⁺ cells was done with the Seurat integrated results as input to build a tree-like differentiation trajectory using the DDRTree algorithm of the R package Monocle v2 ⁵⁹. Select DEGs of B-pDCs, B Cells, and Prog1 populations were set as ordering genes for each trajectory, with the root state set as Prog1 classified cells. Expression of genes as a function of pseudotime was plotted with the plot_genes_branched_pseudotime Monocle function.
Data Deposition

RNA-seq: GSE105827; ChIP-seq: GSE99019; 10x ScRNA-seq: GSE225768. Accession numbers to previously published data sets: GSE52868 (pre-B RNA-seq); GSE55043 (CAL1 ChIP-seq); ENCODE BCL11A ChIP-seq in GM1287838.

Author contributions

Acknowledgements

We thank June V. Harriss for expert assistance in the generation of Bcl11a conditional knockout mice, and Chhaya Das and Maya Ghosh for help in ChIP experiments and cell culture. The CAL1 cell line was kindly provided by Drs. Takahiro Maeda and Boris Reizis. Library preparation and Illumina ChIP- and RNA-seq were performed at the NGS core of the MD Anderson Cancer Center. Single Cell RNA-seq was performed at the University of Texas Genomic Sequencing and Analysis Facility with the help of Holly Stevenson and Dhivya Arasappan. The Lymphoma Research Foundation Fellowship 300463 (to J.D.D.); NIH grant F32CA110624 and Owens Medical Research Foundation grant (to G.C.I.); NIH grant R01AI104870 (to L.I.R.E.); NIH grant R01CA130075 (to V.R.I.); NIH Grant R01CA31534; Cancer Prevention Research Institute of Texas (CPRIT) Grant RP120348 to the MD Anderson NGS core and CPRIT RP120459 and the Marie Betzner Morrow Centennial Endowment (to H.O.T.) provided support for this work.
References


Seth, S. et al. CCR7 Essentially Contributes to the Homing of Plasmacytoid Dendritic Cells to Lymph Nodes under Steady-State As Well As Inflammatory Conditions. The Journal of Immunology 186, 3364-3372, doi:10.4049/jimmunol.1002598 (2011).


53 Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of


Herman JS, Sagar, Grün D. FateID infers cell fate bias in multipotent progenitors from single-cell RNA-seq data. Nat Methods. 2018 May;15(5):379-386. doi: 10.1038/nmeth.4662
**Figure 1**

### A

<table>
<thead>
<tr>
<th>Cell Type/100K</th>
<th>WT</th>
<th>cKO</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>B cells</td>
<td>19,100 ± 2879</td>
<td>7,633 ± 1426</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>pDC</td>
<td>1,086 ± 65</td>
<td>626 ± 63</td>
<td>0.0009</td>
</tr>
</tbody>
</table>

### B

- **pDCs** (B220⁺ Pdca1⁺)
  - **WT**: 1,200 ± 100
  - **cKO**: 600 ± 50
  - **P-value**: ***p=0.0009**

- **B Cells** (B220⁺ Pdca1⁻)
  - **WT**: 2,500 ± 200
  - **cKO**: 500 ± 50
  - **P-value**: ****p<0.0001

### C

#### Bone Marrow

<table>
<thead>
<tr>
<th>WT</th>
<th>cKO</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.6%</td>
<td>1.10%</td>
</tr>
<tr>
<td>5.00%</td>
<td>0.84%</td>
</tr>
</tbody>
</table>

#### Spleen

<table>
<thead>
<tr>
<th>WT</th>
<th>cKO</th>
</tr>
</thead>
<tbody>
<tr>
<td>52.8%</td>
<td>1.18%</td>
</tr>
<tr>
<td>9.75%</td>
<td>0.70%</td>
</tr>
</tbody>
</table>

### D

**Adoptive Transfer Data**

- YFP⁺
- YFP⁻

---

*PDCA1* bone marrow deletion led to a significant decrease in pDCs and B cells in both WT and cKO mice. The reduction was more pronounced in the cKO group for both cell types. The data supports the hypothesis that PDCA1 is essential for the development and/or maintenance of pDCs and B cells.
Figure 2

A. Flow cytometry plots showing gated populations of B220+ PDCA1+ CD11c+ pDCs and YFP pDCs. The YFP pDCs show a 2.06% increase in YFP+ CD11c+ pDCs compared to control.

B. Bar chart showing the fold increase in MHCII(I-A/I-E) expression in YFP+ pDCs compared to control.

C. Flow cytometry plots of spleen cells showing gated populations of B220+ PDCA1+ CD11c+ pDCs and YFP pDCs. The YFP pDCs show a 1.25% increase in YFP+ CD11c+ pDCs compared to control.

D. Bar chart showing the fold increase in pDCs in GpC Control and CpG Stimulated samples.

E. Bar chart showing the fold increase in pDCs in GpC Control and CpG Stimulated samples.

F. Flow cytometry plots of B220+ PDCA1+ CD11c+ splenocytes showing gated populations of CD86+ CD83+ and CD83+ cells.

G. Bar chart showing the fold increase in CD83+ YFP+ pDCs in YFP pDCs and B-pDCs.

H. Bar chart showing the fold increase in IFN-α and IL12-p40 production in pDCs and B-pDCs.

I. Flow cytometry plots showing the percentage of T Cells Alone, B-pDCs + T Cells, and YFP pDCs + T Cells that are live and CD3+. The percentages are 0.27%, 37.3%, and 13.3%, respectively.

J. Bar chart showing the percentage of CSFE negative T Cells in T Cells Alone, B-pDCs, YFP pDCs.
Figure 3
Figure 4
Figure 5

A. 

B. 

C. 

D. 

E. 

F. 

G. 

H. 

I. 

J. 

K. 

L. 

M. 

N. 

O. 

P. 

Q. 

R. 

S. 

T. 

U. 

V. 

W. 

X. 

Y. 

Z. 

Figure 5

Figure 5A: Prog1, B-pDCs, and BCells are plotted on a 2D component map. Prog1 is shown in blue, B-pDCs in green, and BCells in red. The pseudotime scale ranges from 0 to 20.

Figure 5B: Expression levels of Stmn1, Pax5, Siglech, Gata2, Ebf1, Tcf4, Ctl2a, Ms4a1, and Bst2 are plotted against pseudotime. Each gene is shown for Prog1 (blue), B-pDCs (green), and BCells (red). The expression levels are shown for the branches Y_112 (solid line) and Y_83 (dotted line).

Figure 5C: The figure compares the expression patterns of various genes across different cell types and time points.
Supplemental Figure 1

A. Early Progenitors

- **Supplemental Figure 1**

B. Myeloid-Dendritic Progenitors

C. Common Dendritic Progenitor

D. Common Lymphoid Progenitors
Supplemental Figure 2

A

**Bone Marrow**

- WT cKO
  - Macro: CD11b^+ F4/80^+
  - Granulo: CD11b^+ Gr1^hi CD11b^+
  - cDC: CD11b^+ MHCII^+ B220^-
  - CD3^+ T: CD3^+ B220^-
  - CD4^+ T: CD3^+ B220^- CD4^+
  - CD8^+ T: CD3^+ B220^- CD8^+

**Spleen**

- WT cKO
  - Macro: CD11b^+ F4/80^+
  - Granulo: CD11b^+ Gr1^hi CD11b^+
  - cDC: CD11b^+ MHCII^+ B220^-
  - CD3^+ T: CD3^+ B220^- CD4^+
  - CD4^+ T: CD3^+ B220^- CD8^+
  - CD8^+ T: CD3^+ B220^- CD8^+

* p=0.025
* p=0.007
* p=0.006
Supplemental Figure 3
Supplemental Figure 4

A. Gating Hierarchy

B. Flow Cytometry

C. Flow Cytometry Gating

D. Flow Cytometry Table

E. Graph of Axl+ Cells

Supplemental Figure 4
Supplemental Figure 6

A.

- **Ighm**
- **J Chain**
- **Ly6d**
- **Igkc**
- **Iglc2**
- **Xbp1**

Pseudotime

B.

- **SSC-A**
- **SSC-H**
- **FSC-A**
- **Viability**
- **CD138**
- **B220**
- **PDCA1**
- **CD23**

**de facto Plasma Cells**

94.1 95.5 90.1% 0.92% 1.78% 29.2% 0.26% 88.7% 10.6% 0.45% 10.1% 0.14% 2.0% 0.92%
<table>
<thead>
<tr>
<th>Cluster</th>
<th>Ref. Cell Type</th>
<th>CIPR Ref. ID</th>
<th>Consensus ID</th>
<th>ID Score</th>
<th>Z Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>X0</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC3</td>
<td>0.87</td>
<td>2.92</td>
</tr>
<tr>
<td>X1</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC2</td>
<td>0.87</td>
<td>3.05</td>
</tr>
<tr>
<td>X2</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC4</td>
<td>0.86</td>
<td>2.69</td>
</tr>
<tr>
<td>X3</td>
<td>Macrophage</td>
<td>MF.Thio5.II+480</td>
<td>Mac1</td>
<td>0.79</td>
<td>2.46</td>
</tr>
<tr>
<td>X4</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC5</td>
<td>0.84</td>
<td>2.88</td>
</tr>
<tr>
<td>X5</td>
<td>Macrophage</td>
<td>MF.11cloSer.SI</td>
<td>Mac3</td>
<td>0.82</td>
<td>2.40</td>
</tr>
<tr>
<td>X6</td>
<td>Monocyte</td>
<td>Mo.6+2+.BL</td>
<td>Mono1</td>
<td>0.84</td>
<td>2.55</td>
</tr>
<tr>
<td>X7</td>
<td>Monocyte</td>
<td>Mo.6C-llint.Bl</td>
<td>Mono2</td>
<td>0.85</td>
<td>3.02</td>
</tr>
<tr>
<td>X8</td>
<td>B cell</td>
<td>B.Fo.Sp</td>
<td>B Cells</td>
<td>0.82</td>
<td>1.93</td>
</tr>
<tr>
<td>X9</td>
<td>Stem-Progenitor</td>
<td>SC.CDP.BM</td>
<td>Prog2</td>
<td>0.83</td>
<td>2.16</td>
</tr>
<tr>
<td>X10</td>
<td>Granulocyte</td>
<td>GN.BM</td>
<td>Granul3</td>
<td>0.81</td>
<td>3.41</td>
</tr>
<tr>
<td>X11</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC1</td>
<td>0.84</td>
<td>3.10</td>
</tr>
<tr>
<td>X12</td>
<td>Granulocyte</td>
<td>GN.BM</td>
<td>Granul1</td>
<td>0.76</td>
<td>2.18</td>
</tr>
<tr>
<td>X13</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC7</td>
<td>0.75</td>
<td>2.19</td>
</tr>
<tr>
<td>X14</td>
<td>Granulocyte</td>
<td>GN.BM</td>
<td>Granul2</td>
<td>0.75</td>
<td>2.74</td>
</tr>
<tr>
<td>X15</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC6</td>
<td>0.81</td>
<td>1.91</td>
</tr>
<tr>
<td>X16</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>B-pDC</td>
<td>0.75</td>
<td>2.25</td>
</tr>
<tr>
<td>X17</td>
<td>Macrophage</td>
<td>MF.II+480lo.PC</td>
<td>Mac2</td>
<td>0.75</td>
<td>2.11</td>
</tr>
<tr>
<td>X18</td>
<td>Stem-Progenitor</td>
<td>MLP.BM</td>
<td>Prog1</td>
<td>0.79</td>
<td>2.18</td>
</tr>
<tr>
<td>X19</td>
<td>NK cell</td>
<td>NK.DAP10-.Sp</td>
<td>NK Cells</td>
<td>0.72</td>
<td>1.41</td>
</tr>
<tr>
<td>X20</td>
<td>Monocyte</td>
<td>Mo.6C+ll-.LN</td>
<td>Mono3</td>
<td>0.69</td>
<td>1.73</td>
</tr>
<tr>
<td>X21</td>
<td>DC</td>
<td>DC.pDC.8-.Sp</td>
<td>pDC8</td>
<td>0.62</td>
<td>2.97</td>
</tr>
<tr>
<td>Marker</td>
<td>p_val</td>
<td>avg_log2FC</td>
<td>pct.1</td>
<td>pct.2</td>
<td>p_val_adj</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>------------</td>
<td>-------</td>
<td>-------</td>
<td>-----------</td>
</tr>
<tr>
<td>Jchain</td>
<td>0</td>
<td>8.374583</td>
<td>0.968</td>
<td>0.01</td>
<td>0</td>
</tr>
<tr>
<td>Igcl1</td>
<td>0</td>
<td>7.384079</td>
<td>0.753</td>
<td>0.024</td>
<td>0</td>
</tr>
<tr>
<td>Igcl2</td>
<td>0</td>
<td>6.93436</td>
<td>0.876</td>
<td>0.039</td>
<td>0</td>
</tr>
<tr>
<td>Ckap4</td>
<td>0</td>
<td>2.288614</td>
<td>0.817</td>
<td>0.05</td>
<td>0</td>
</tr>
<tr>
<td>Cd79a</td>
<td>0</td>
<td>2.130392</td>
<td>0.683</td>
<td>0.005</td>
<td>0</td>
</tr>
<tr>
<td>Igvl</td>
<td>0</td>
<td>2.07227</td>
<td>0.366</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Derf3</td>
<td>0</td>
<td>1.951565</td>
<td>0.608</td>
<td>0.007</td>
<td>0</td>
</tr>
<tr>
<td>Chst1</td>
<td>0</td>
<td>1.843237</td>
<td>0.478</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cd81</td>
<td>0</td>
<td>1.748841</td>
<td>0.731</td>
<td>0.045</td>
<td>0</td>
</tr>
<tr>
<td>Pou2af1</td>
<td>0</td>
<td>1.408274</td>
<td>0.511</td>
<td>0.001</td>
<td>0</td>
</tr>
<tr>
<td>Prq2</td>
<td>0</td>
<td>1.221508</td>
<td>0.484</td>
<td>0.002</td>
<td>0</td>
</tr>
<tr>
<td>Eaf2</td>
<td>0</td>
<td>1.203375</td>
<td>0.495</td>
<td>0.011</td>
<td>0</td>
</tr>
<tr>
<td>Fkbp11</td>
<td>0</td>
<td>0.971198</td>
<td>0.425</td>
<td>0.007</td>
<td>0</td>
</tr>
<tr>
<td>Cacna1s</td>
<td>0</td>
<td>0.816281</td>
<td>0.376</td>
<td>0.004</td>
<td>0</td>
</tr>
<tr>
<td>Tnfrsf17</td>
<td>0</td>
<td>0.810065</td>
<td>0.306</td>
<td>0.001</td>
<td>0</td>
</tr>
<tr>
<td>Lax1</td>
<td>0</td>
<td>0.653721</td>
<td>0.333</td>
<td>0.004</td>
<td>0</td>
</tr>
<tr>
<td>Rapgef3</td>
<td>0</td>
<td>0.63881</td>
<td>0.317</td>
<td>0.002</td>
<td>0</td>
</tr>
<tr>
<td>Oosp1</td>
<td>0</td>
<td>0.549178</td>
<td>0.306</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cacna1h</td>
<td>0</td>
<td>0.3548</td>
<td>0.274</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fam46c</td>
<td>1.94E-290</td>
<td>1.973402</td>
<td>0.758</td>
<td>0.059</td>
<td>3.13E-286</td>
</tr>
<tr>
<td>Prdm1</td>
<td>5.50E-274</td>
<td>0.655727</td>
<td>0.29</td>
<td>0.006</td>
<td>8.90E-270</td>
</tr>
<tr>
<td>St8sia6</td>
<td>1.28E-266</td>
<td>0.668541</td>
<td>0.269</td>
<td>0.005</td>
<td>2.07E-262</td>
</tr>
<tr>
<td>Igga</td>
<td>3.09E-214</td>
<td>8.551656</td>
<td>0.328</td>
<td>0.013</td>
<td>5.00E-210</td>
</tr>
<tr>
<td>Slamf7</td>
<td>5.60E-210</td>
<td>1.233262</td>
<td>0.527</td>
<td>0.038</td>
<td>9.07E-206</td>
</tr>
<tr>
<td>Egr1</td>
<td>5.09E-205</td>
<td>1.653236</td>
<td>0.505</td>
<td>0.035</td>
<td>8.24E-201</td>
</tr>
<tr>
<td>Igkc</td>
<td>1.18E-157</td>
<td>9.329484</td>
<td>0.935</td>
<td>0.258</td>
<td>1.91E-153</td>
</tr>
<tr>
<td>Ikkf3</td>
<td>9.76E-139</td>
<td>0.655167</td>
<td>0.339</td>
<td>0.022</td>
<td>1.58E-134</td>
</tr>
<tr>
<td>Atxn1</td>
<td>5.14E-137</td>
<td>0.502322</td>
<td>0.274</td>
<td>0.014</td>
<td>8.32E-133</td>
</tr>
<tr>
<td>Edem1</td>
<td>6.09E-130</td>
<td>2.247955</td>
<td>0.833</td>
<td>0.192</td>
<td>9.86E-126</td>
</tr>
<tr>
<td>Dennd5b</td>
<td>3E-121</td>
<td>1.202647</td>
<td>0.5</td>
<td>0.06</td>
<td>4.8E-117</td>
</tr>
<tr>
<td>Serpina3g</td>
<td>8.8E-111</td>
<td>0.446503</td>
<td>0.258</td>
<td>0.016</td>
<td>1.4E-106</td>
</tr>
<tr>
<td>Kcn4</td>
<td>1.3E-110</td>
<td>0.746446</td>
<td>0.473</td>
<td>0.056</td>
<td>2.1E-106</td>
</tr>
<tr>
<td>Ptpn22</td>
<td>1.7E-109</td>
<td>0.487952</td>
<td>0.263</td>
<td>0.017</td>
<td>2.7E-105</td>
</tr>
<tr>
<td>Bst2</td>
<td>1.9E-107</td>
<td>-2.55211</td>
<td>0.812</td>
<td>0.981</td>
<td>3E-103</td>
</tr>
<tr>
<td>Tmem176b</td>
<td>4.5E-104</td>
<td>1.21053</td>
<td>0.581</td>
<td>0.094</td>
<td>7.2E-100</td>
</tr>
<tr>
<td>Tram2</td>
<td>1.8E-100</td>
<td>0.898306</td>
<td>0.435</td>
<td>0.052</td>
<td>2.87E-96</td>
</tr>
<tr>
<td>Tyrobp</td>
<td>2.8E-100</td>
<td>-2.93301</td>
<td>0.543</td>
<td>0.966</td>
<td>4.46E-96</td>
</tr>
<tr>
<td>Rgcc</td>
<td>8.2E-100</td>
<td>0.698419</td>
<td>0.392</td>
<td>0.043</td>
<td>1.32E-95</td>
</tr>
<tr>
<td>Plac8</td>
<td>1.1E-99</td>
<td>-2.74335</td>
<td>0.532</td>
<td>0.968</td>
<td>1.79E-95</td>
</tr>
<tr>
<td>Fau</td>
<td>1.1E-99</td>
<td>-1.51384</td>
<td>0.978</td>
<td>0.99</td>
<td>1.8E-95</td>
</tr>
<tr>
<td>Tmem176a</td>
<td>2.11E-94</td>
<td>1.147371</td>
<td>0.505</td>
<td>0.078</td>
<td>3.42E-90</td>
</tr>
<tr>
<td>Siglech</td>
<td>2.15E-94</td>
<td>-2.43541</td>
<td>0.435</td>
<td>0.975</td>
<td>3.48E-90</td>
</tr>
<tr>
<td>Rpl19</td>
<td>5.61E-93</td>
<td>-1.60971</td>
<td>0.898</td>
<td>0.974</td>
<td>9.08E-89</td>
</tr>
<tr>
<td>Rpl31</td>
<td>6.64E-93</td>
<td>-2.11381</td>
<td>0.726</td>
<td>0.969</td>
<td>1.07E-88</td>
</tr>
<tr>
<td>Rpl30</td>
<td>3.32E-92</td>
<td>-1.46995</td>
<td>0.919</td>
<td>0.984</td>
<td>5.38E-88</td>
</tr>
<tr>
<td>Man1a</td>
<td>5.39E-92</td>
<td>0.950944</td>
<td>0.516</td>
<td>0.078</td>
<td>8.73E-88</td>
</tr>
<tr>
<td>Mzb1</td>
<td>1.5E-91</td>
<td>2.698237</td>
<td>0.844</td>
<td>0.311</td>
<td>2.42E-87</td>
</tr>
<tr>
<td>Rps11</td>
<td>1.83E-90</td>
<td>-1.62328</td>
<td>0.93</td>
<td>0.983</td>
<td>2.95E-86</td>
</tr>
<tr>
<td>Rpl18a</td>
<td>2.41E-90</td>
<td>-1.47776</td>
<td>0.898</td>
<td>0.981</td>
<td>3.89E-86</td>
</tr>
</tbody>
</table>
**Figure 1**

**A**

<table>
<thead>
<tr>
<th>Cell Type/100K</th>
<th>WT</th>
<th>cKO</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>B cells</td>
<td>19,100 ± 2879</td>
<td>7,633 ± 1426</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>pDC</td>
<td>1,086 ± 65</td>
<td>626 ± 63</td>
<td>0.00009</td>
</tr>
</tbody>
</table>

**B**

- **pDCs** (B220⁺ PDca1⁺)
  - WT: 1200 ± 100
  - cKO: 600 ± 50
  - ***p=0.0009**

- **B Cells** (B220⁺ PDca1⁻)
  - WT: 2500 ± 200
  - cKO: 250 ± 25
  - ****p<0.0001**

**Adoptive Transfer Data**

**C**

**Bone Marrow**

- WT: 16.6% 1.10%
- cKO: 5.00% 0.84%

**D**

**Spleen**

- WT: 52.8% 1.18%
- cKO: 9.75% 0.70%

**E**

- #B cells (B220⁺ PDca1⁻)
  - WT: 6000 ± 500
  - cKO: 3000 ± 300
  - *p<0.030*

**F**

- #pDCs cells (B220⁺ PDca1⁺ CD11c⁺)
  - WT: 1200 ± 120
  - cKO: 600 ± 60
  - p=0.06 (NS)

- % of pDCs
  - WT: 80 ± 8
  - cKO: 40 ± 4
  - *p=0.011*
Figure 2
Figure 3
Figure 4
Figure 5